Dataset: A 13-gene signature prognostic of HPV-negative OSCC: discovery and external validation
OSCC is associated with substantial mortality and morbidity. In this study, we built on our previous molecular work to identify and...
OSCC is associated with substantial mortality and morbidity. In this study, we built on our previous molecular work to identify and validate a prognostic 13-gene signature that showed a higher ability than tumor stage in predicting survival for patients with HPV-negative oral squamous cell carcinoma (OSCC). We previously reported 131 genes to be associated with survival in OSCC patients. In this study, we applied L1/L2-penalized Cox regression models to the Affymetrix array data from 97 HPV-negative OSCC patients on the 131 gene to identify a model for prediction of OSCC-specific survival. We then tested the model in an independent dataset and compared to tumor stage.
- Species:
- human
- Samples:
- 97
- Source:
- E-GEOD-41613
- PubMed:
- 23319825
- Updated:
- Dec.12, 2014
- Registered:
- Jul.12, 2014
Sample | AGE | TUMOR STAGE | SEX | VITAL | TREATMENT | FU TIME |
---|---|---|---|---|---|---|
GSM1020195 | 60-88 | I/II | male | alive | uni-modality | 52.60 |
GSM1020194 | 60-88 | I/II | female | alive | uni-modality | 53.88 |
GSM1020193 | 60-88 | I/II | female | alive | uni-modality | 54.41 |
GSM1020192 | 40-49 | I/II | male | alive | uni-modality | 54.57 |
GSM102019 | 19-39 | III/IV | female | Dead-oral ca | multii-modality | 8.38 |
GSM1020190 | 50-59 | III/IV | male | Dead -unk cause | multii-modality | 20.01 |
GSM1020189 | 60-88 | I/II | male | alive | uni-modality | 55.10 |
GSM1020188 | 60-88 | I/II | male | alive | multii-modality | 56.02 |
GSM1020187 | 60-88 | III/IV | male | Dead-non OC | uni-modality | 0.46 |
GSM1020186 | 40-49 | I/II | male | alive | uni-modality | 57.53 |
GSM1020185 | 60-88 | III/IV | male | Dead-oral ca | multii-modality | 6.54 |
GSM1020184 | 50-59 | I/II | male | Dead-non OC | multii-modality | 14.42 |
GSM1020183 | 60-88 | I/II | male | Dead-non OC | uni-modality | 35.38 |
GSM1020182 | 50-59 | III/IV | male | Dead-non OC | multii-modality | 17.02 |
GSM102018 | 50-59 | III/IV | male | Dead-non OC | multii-modality | 45.93 |
GSM1020180 | 40-49 | III/IV | male | alive | multii-modality | 57.63 |
GSM1020179 | 60-88 | I/II | male | alive | uni-modality | 62.85 |
GSM1020178 | 60-88 | III/IV | female | Dead-non OC | uni-modality | 1.22 |
GSM1020177 | 60-88 | I/II | female | alive | uni-modality | 58.71 |
GSM1020176 | 60-88 | III/IV | male | Dead-oral ca | multii-modality | 6.90 |
GSM1020175 | 50-59 | I/II | male | alive | uni-modality | 59.24 |
GSM1020174 | 40-49 | III/IV | male | Dead-oral ca | multii-modality | 9.23 |
GSM1020173 | 60-88 | I/II | male | Dead-oral ca | uni-modality | 9.86 |
GSM1020172 | 60-88 | I/II | female | alive | multii-modality | 59.96 |
GSM102017 | 60-88 | III/IV | male | alive | multii-modality | 60.65 |
GSM1020170 | 60-88 | I/II | male | alive | uni-modality | 61.01 |
GSM1020169 | 50-59 | III/IV | male | alive | multii-modality | 59.47 |
GSM1020168 | 40-49 | III/IV | male | alive | multii-modality | 61.08 |
GSM1020167 | 50-59 | III/IV | female | Dead -unk cause | multii-modality | 51.61 |
GSM1020166 | 60-88 | I/II | male | alive | uni-modality | 61.73 |
GSM1020165 | 60-88 | III/IV | male | Dead-oral ca | uni-modality | 19.12 |
GSM1020164 | 60-88 | III/IV | male | alive | multii-modality | 61.54 |
GSM1020163 | 60-88 | III/IV | male | alive | uni-modality | 60.55 |
GSM1020162 | 60-88 | III/IV | female | Dead-oral ca | multii-modality | 35.12 |
GSM102016 | 50-59 | I/II | male | alive | uni-modality | 63.38 |
GSM1020160 | 60-88 | I/II | male | alive | uni-modality | 63.54 |
GSM1020159 | 40-49 | III/IV | female | alive | multii-modality | 65.45 |
GSM1020158 | 50-59 | III/IV | male | Dead-oral ca | multii-modality | 10.68 |
GSM1020157 | 60-88 | III/IV | male | Dead-oral ca | uni-modality | 2.40 |
GSM1020156 | 60-88 | I/II | male | alive | uni-modality | 65.22 |
GSM1020155 | 19-39 | I/II | male | alive | uni-modality | 66.56 |
GSM1020154 | 50-59 | I/II | male | alive | multii-modality | 66.60 |
GSM1020153 | 19-39 | III/IV | male | alive | multii-modality | 67.55 |
GSM1020152 | 50-59 | I/II | male | Dead-non OC | uni-modality | 19.65 |
GSM102015 | 60-88 | I/II | female | alive | uni-modality | 67.94 |
GSM1020150 | 60-88 | III/IV | male | alive | multii-modality | 68.14 |
GSM1020149 | 50-59 | I/II | female | alive | multii-modality | 70.08 |
GSM1020148 | 19-39 | I/II | female | alive | uni-modality | 70.08 |
GSM1020147 | 50-59 | I/II | female | alive | uni-modality | 69.16 |
GSM1020146 | 60-88 | III/IV | female | Dead-oral ca | multii-modality | 6.44 |
GSM1020145 | 60-88 | III/IV | male | Dead-oral ca | multii-modality | 12.29 |
GSM1020144 | 60-88 | III/IV | female | alive | multii-modality | 68.47 |
GSM1020143 | 50-59 | I/II | male | Dead -unk cause | uni-modality | 64.99 |
GSM1020142 | 50-59 | III/IV | male | alive | multii-modality | 73.26 |
GSM102014 | 60-88 | III/IV | male | alive | multii-modality | 72.28 |
GSM1020140 | 60-88 | I/II | male | alive | uni-modality | 73.17 |
GSM1020139 | 19-39 | III/IV | male | Dead-oral ca | multii-modality | 14.75 |
GSM1020138 | 50-59 | I/II | female | alive | uni-modality | 74.64 |
GSM1020137 | 60-88 | III/IV | male | Dead-non OC | multii-modality | 43.24 |
GSM1020136 | 60-88 | I/II | male | alive | uni-modality | 75.07 |
GSM1020135 | 50-59 | III/IV | female | Dead-non OC | multii-modality | 26.81 |
GSM1020134 | 40-49 | I/II | male | Dead-oral ca | multii-modality | 29.14 |
GSM1020133 | 60-88 | I/II | male | alive | multii-modality | 76.85 |
GSM1020132 | 50-59 | III/IV | male | Dead-oral ca | multii-modality | 20.11 |
GSM102013 | 60-88 | III/IV | female | Dead-oral ca | multii-modality | 24.87 |
GSM1020130 | 60-88 | III/IV | male | Dead-oral ca | unknown | 3.52 |
GSM1020129 | 60-88 | III/IV | female | Dead -unk cause | multii-modality | 76.75 |
GSM1020128 | 50-59 | III/IV | female | Dead-non OC | uni-modality | 41.17 |
GSM1020127 | 60-88 | III/IV | male | alive | multii-modality | 78.95 |
GSM1020126 | 60-88 | I/II | female | Dead -unk cause | uni-modality | 35.45 |
GSM1020125 | 19-39 | III/IV | female | Dead-oral ca | multii-modality | 5.85 |
GSM1020124 | 60-88 | III/IV | female | Dead-oral ca | multii-modality | 24.25 |
GSM1020123 | 40-49 | III/IV | male | Dead-oral ca | uni-modality | 21.78 |
GSM1020122 | 50-59 | I/II | female | Dead-non OC | multii-modality | 18.40 |
GSM102012 | 40-49 | III/IV | female | Dead-oral ca | multii-modality | 15.41 |
GSM1020120 | 40-49 | I/II | male | alive | uni-modality | 80.79 |
GSM1020119 | 50-59 | III/IV | male | alive | multii-modality | 80.16 |
GSM1020118 | 40-49 | III/IV | female | Dead-oral ca | uni-modality | 15.31 |
GSM1020117 | 50-59 | III/IV | male | Dead -unk cause | uni-modality | 9.92 |
GSM1020116 | 40-49 | III/IV | male | Dead -unk cause | multii-modality | 78.29 |
GSM1020115 | 50-59 | III/IV | male | Dead-non OC | multii-modality | 66.63 |
GSM1020114 | 60-88 | I/II | male | Dead-oral ca | uni-modality | 7.23 |
GSM1020113 | 50-59 | III/IV | male | Dead-oral ca | multii-modality | 7.16 |
GSM1020112 | 60-88 | I/II | male | alive | uni-modality | 81.51 |
GSM1020 | 50-59 | III/IV | male | Dead-non OC | uni-modality | 28.52 |
GSM1020110 | 40-49 | III/IV | male | Dead-oral ca | multii-modality | 10.05 |
GSM1020109 | 60-88 | III/IV | male | Dead-oral ca | multii-modality | 14.16 |
GSM1020108 | 60-88 | III/IV | female | alive | multii-modality | 82.92 |
GSM1020107 | 50-59 | III/IV | male | Dead-oral ca | multii-modality | 46.88 |
GSM1020106 | 60-88 | I/II | female | alive | uni-modality | 84.24 |
GSM1020105 | 60-88 | III/IV | female | Dead-oral ca | multii-modality | 40.71 |
GSM1020104 | 40-49 | III/IV | female | alive | multii-modality | 85.03 |
GSM1020103 | 40-49 | I/II | male | Dead-oral ca | uni-modality | 28.62 |
GSM1020102 | 60-88 | III/IV | male | Dead-non OC | multii-modality | 3.38 |
GSM102010 | 50-59 | III/IV | male | Dead-oral ca | multii-modality | 6.54 |
GSM1020100 | 50-59 | I/II | male | Dead-oral ca | uni-modality | 55.66 |
GSM1020099 | 40-49 | I/II | female | alive | uni-modality | 62.85 |